{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T07:09:34Z","timestamp":1760425774808,"version":"3.37.3"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,10,22]],"date-time":"2019-10-22T00:00:00Z","timestamp":1571702400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,10,22]],"date-time":"2019-10-22T00:00:00Z","timestamp":1571702400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n              <jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>PMM2-CDG (Phosphomannomutase 2 -\u00a0Congenital disorder of glycosylation-Ia; CDG-Ia) is the most common glycosylation defect, often presenting as a severe multisystem disorder that can be fatal within the first years of life. While mannose treatment has been shown to correct glycosylation in vitro and in vivo in mice, no convincing effects have been observed in short-term treatment trials in single patients so far.<\/jats:p>\n              <\/jats:sec>\n              <jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>We report on a boy with a severe PMM2-CDG who received a continuous intravenous mannose infusion over a period of 5\u2009months during the first year of life in a dose of 0.8\u2009g\/kg\/day. N-glycosylation of serum glycoproteins and mannose concentrations in serum were studied regularly. Unfortunately, no biochemical or clinical improvement was observed, and the therapy was terminated at age 9\u2009months.<\/jats:p>\n              <\/jats:sec>\n              <jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Postnatal intravenous D-mannose treatment seems to be ineffective in PMM2-CDG.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13023-019-1213-3","type":"journal-article","created":{"date-parts":[[2019,10,23]],"date-time":"2019-10-23T04:28:23Z","timestamp":1571804903000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Unsuccessful intravenous D-mannose treatment in PMM2-CDG"],"prefix":"10.1186","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5986-0468","authenticated-orcid":false,"given":"Sarah C.","family":"Gr\u00fcnert","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thorsten","family":"Marquardt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ekkehart","family":"Lausch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hans","family":"Fuchs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Thiel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Sutter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anke","family":"Schumann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luciana","family":"Hannibal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ute","family":"Spiekerkoetter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,10,22]]},"reference":[{"key":"1213_CR1","volume-title":"GeneReviews\u00ae","author":"SE Sparks","year":"1993","unstructured":"Sparks SE, Krasnewich DM. PMM2-CDG (CDG-Ia). In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJ, Stephens K, et al., editors. GeneReviews\u00ae. Seattle: University of Washington, Seattle; 1993. \n                    http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK1110\/\n                    \n                  . Accessed 5 Feb 2019."},{"key":"1213_CR2","doi-asserted-by":"publisher","first-page":"2182","DOI":"10.1093\/hmg\/ddw085","volume":"25","author":"B Chan","year":"2016","unstructured":"Chan B, Clasquin M, Smolen GA, Histen G, Powe J, Chen Y, et al. A mouse model of a human congenital disorder of glycosylation caused by loss of PMM2. Hum Mol Genet. 2016;25:2182\u201393.","journal-title":"Hum Mol Genet"},{"key":"1213_CR3","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1006\/bmme.1997.2599","volume":"61","author":"K Panneerselvam","year":"1997","unstructured":"Panneerselvam K, Etchison JR, Skovby F, Freeze HH. Abnormal metabolism of mannose in families with carbohydrate-deficient glycoprotein syndrome type 1. Biochem Mol Med. 1997;61:161\u20137.","journal-title":"Biochem Mol Med"},{"key":"1213_CR4","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.1172\/JCI118570","volume":"97","author":"K Panneerselvam","year":"1996","unstructured":"Panneerselvam K, Freeze HH. Mannose corrects altered N-glycosylation in carbohydrate-deficient glycoprotein syndrome fibroblasts. J Clin Invest. 1996;97:1478\u201387.","journal-title":"J Clin Invest"},{"key":"1213_CR5","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1093\/glycob\/10.8.829","volume":"10","author":"JS Rush","year":"2000","unstructured":"Rush JS, Panneerselvam K, Waechter CJ, Freeze HH. Mannose supplementation corrects GDP-mannose deficiency in cultured fibroblasts from some patients with Congenital Disorders of Glycosylation (CDG). Glycobiology. 2000;10:829\u201335.","journal-title":"Glycobiology"},{"key":"1213_CR6","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1023\/A:1006939104442","volume":"15","author":"C K\u00f6rner","year":"1998","unstructured":"K\u00f6rner C, Lehle L, von Figura K. Carbohydrate-deficient glycoprotein syndrome type 1: correction of the glycosylation defect by deprivation of glucose or supplementation of mannose. Glycoconj J. 1998;15:499\u2013505.","journal-title":"Glycoconj J"},{"key":"1213_CR7","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1038\/nm.2548","volume":"18","author":"A Schneider","year":"2011","unstructured":"Schneider A, Thiel C, Rindermann J, DeRossi C, Popovici D, Hoffmann GF, et al. Successful prenatal mannose treatment for congenital disorder of glycosylation-Ia in mice. Nat Med. 2011;18:71\u20133.","journal-title":"Nat Med"},{"key":"1213_CR8","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1111\/j.1651-2227.1998.tb01556.x","volume":"87","author":"S Kjaergaard","year":"1998","unstructured":"Kjaergaard S, Kristiansson B, Stibler H, Freeze HH, Schwartz M, Martinsson T, et al. Failure of short-term mannose therapy of patients with carbohydrate-deficient glycoprotein syndrome type 1A. Acta Paediatr. 1998;87:884\u20138.","journal-title":"Acta Paediatr"},{"key":"1213_CR9","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1007\/s004310050889","volume":"157","author":"E Mayatepek","year":"1998","unstructured":"Mayatepek E, Kohlm\u00fcller D. Mannose supplementation in carbohydrate-deficient glycoprotein syndrome type I and phosphomannomutase deficiency. Eur J Pediatr. 1998;157:605\u20136.","journal-title":"Eur J Pediatr"},{"key":"1213_CR10","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1111\/j.1651-2227.1997.tb14825.x","volume":"86","author":"E Mayatepek","year":"1997","unstructured":"Mayatepek E, Schr\u00f6der M, Kohlm\u00fcller D, Bieger WP, N\u00fctzenadel W. Continuous mannose infusion in carbohydrate-deficient glycoprotein syndrome type I. Acta Paediatr. 1997;86:1138\u201340.","journal-title":"Acta Paediatr"},{"key":"1213_CR11","doi-asserted-by":"crossref","unstructured":"Brasil S, Pascoal C, Francisco R, Marques-da-Silva D, Andreotti G, Videira PA, et al. CDG therapies: from bench to bedside. Int J Mol Sci. 2018;19(5) pii: E1304","DOI":"10.3390\/ijms19051304"},{"key":"1213_CR12","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.1172\/JCI2350","volume":"101","author":"R Niehues","year":"1998","unstructured":"Niehues R, Hasilik M, Alton G, K\u00f6rner C, Schiebe-Sukumar M, Koch HG, et al. Carbohydrate-deficient glycoprotein syndrome type Ib. Phosphomannose isomerase deficiency and mannose therapy. J Clin Invest. 1998;101:1414\u201320.","journal-title":"J Clin Invest"},{"key":"1213_CR13","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1086\/318199","volume":"68","author":"S Gr\u00fcnewald","year":"2001","unstructured":"Gr\u00fcnewald S, Schollen E, Van Schaftingen E, Jaeken J, Matthijs G. High residual activity of PMM2 in patients\u2019 fibroblasts: possible pitfall in the diagnosis of CDG-Ia (phosphomannomutase deficiency). Am J Hum Genet. 2001;68:347\u201354.","journal-title":"Am J Hum Genet"},{"key":"1213_CR14","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1002\/humu.9336","volume":"25","author":"C Le Bizec","year":"2005","unstructured":"Le Bizec C, Vuillaumier-Barrot S, Barnier A, Dupr\u00e9 T, Durand G, Seta N. A new insight into PMM2 mutations in the French population. Hum Mutat. 2005;25:504\u20135.","journal-title":"Hum Mutat"},{"key":"1213_CR15","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/S0014-5793(99)00673-0","volume":"452","author":"M Pirard","year":"1999","unstructured":"Pirard M, Matthijs G, Heykants L, Schollen E, Gr\u00fcnewald S, Jaeken J, et al. Effect of mutations found in carbohydrate-deficient glycoprotein syndrome type IA on the activity of phosphomannomutase 2. FEBS Lett. 1999;452:319\u201322.","journal-title":"FEBS Lett"},{"key":"1213_CR16","doi-asserted-by":"publisher","first-page":"14918","DOI":"10.1074\/jbc.M601505200","volume":"281","author":"NR Silvaggi","year":"2006","unstructured":"Silvaggi NR, Zhang C, Lu Z, Dai J, Dunaway-Mariano D, Allen KN. The X-ray crystal structures of human alpha-phosphomannomutase 1 reveal the structural basis of congenital disorder of glycosylation type 1a. J Biol Chem. 2006;281:14918\u201326.","journal-title":"J Biol Chem"},{"key":"1213_CR17","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1006\/bmme.1997.2574","volume":"60","author":"G Alton","year":"1997","unstructured":"Alton G, Kjaergaard S, Etchison JR, Skovby F, Freeze HH. Oral ingestion of mannose elevates blood mannose levels: a first step toward a potential therapy for carbohydrate-deficient glycoprotein syndrome type I. Biochem Mol Med. 1997;60:127\u201333.","journal-title":"Biochem Mol Med"},{"key":"1213_CR18","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1038\/nsmb.3368","volume":"24","author":"B Hummel","year":"2017","unstructured":"Hummel B, Hansen EC, Yoveva A, Aprile-Garcia F, Hussong R, Sawarkar R. The evolutionary capacitor HSP90 buffers the regulatory effects of mammalian endogenous retroviruses. Nat Struct Mol Biol. 2017;24:234\u201342.","journal-title":"Nat Struct Mol Biol"},{"key":"1213_CR19","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1016\/j.cell.2017.01.023","volume":"168","author":"GI Karras","year":"2017","unstructured":"Karras GI, Yi S, Sahni N, Fischer M, Xie J, Vidal M, et al. HSP90 shapes the consequences of human genetic variation. Cell. 2017;168:856\u201366 e12.","journal-title":"Cell"},{"key":"1213_CR20","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1038\/nature22487","volume":"545","author":"ML Siegal","year":"2017","unstructured":"Siegal ML. Molecular genetics: chaperone protein gets personal. Nature. 2017;545:36\u20137.","journal-title":"Nature"},{"key":"1213_CR21","doi-asserted-by":"publisher","first-page":"34900","DOI":"10.1074\/jbc.M114.586362","volume":"289","author":"G Andreotti","year":"2014","unstructured":"Andreotti G, Cabeza de Vaca I, Poziello A, Monti MC, Guallar V, Cubellis MV. Conformational response to ligand binding in phosphomannomutase2: insights into inborn glycosylation disorder. J Biol Chem. 2014;289:34900\u201310.","journal-title":"J Biol Chem"},{"key":"1213_CR22","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1074\/mcp.M115.054122","volume":"15","author":"CT Thiesler","year":"2016","unstructured":"Thiesler CT, Cajic S, Hoffmann D, Thiel C, van Diepen L, Hennig R, et al. Glycomic characterization of induced pluripotent stem cells derived from a patient suffering from phosphomannomutase 2 congenital disorder of glycosylation (PMM2-CDG). Mol Cell Proteomics. 2016;15:1435\u201352.","journal-title":"Mol Cell Proteomics"},{"key":"1213_CR23","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1093\/glycob\/cwj006","volume":"15","author":"EA Eklund","year":"2005","unstructured":"Eklund EA, Merbouh N, Ichikawa M, Nishikawa A, Clima JM, Dorman JA, et al. Hydrophobic Man-1-P derivatives correct abnormal glycosylation in type I congenital disorder of glycosylation fibroblasts. Glycobiology. 2005;15:1084\u201393.","journal-title":"Glycobiology"},{"key":"1213_CR24","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.bmcl.2006.09.074","volume":"17","author":"R Hardr\u00e9","year":"2007","unstructured":"Hardr\u00e9 R, Khaled A, Willemetz A, Dupr\u00e9 T, Moore S, Gravier-Pelletier C, et al. Mono, di and tri-mannopyranosyl phosphates as mannose-1-phosphate prodrugs for potential CDG-Ia therapy. Bioorg Med Chem Lett. 2007;17:152\u20135.","journal-title":"Bioorg Med Chem Lett"},{"key":"1213_CR25","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1002\/ana.25457","volume":"85","author":"AF Mart\u00ednez-Monseny","year":"2019","unstructured":"Mart\u00ednez-Monseny AF, Bolasell M, Callej\u00f3n-P\u00f3o L, Cuadras D, Freniche V, Itzep DC, et al. AZATAX: acetazolamide safety and efficacy in cerebellar syndrome in PMM2 congenital disorder of glycosylation (PMM2-CDG). Ann Neurol. 2019;85:740\u201351.","journal-title":"Ann Neurol"},{"key":"1213_CR26","doi-asserted-by":"crossref","unstructured":"Izquierdo-Serra M, Mart\u00ednez-Monseny AF, L\u00f3pez L, Carrillo-Garc\u00eda J, Edo A, Ortigoza-Escobar JD, et al. Stroke-like episodes and cerebellar syndrome in phosphomannomutase deficiency (PMM2-CDG): evidence for hypoglycosylation-driven channelopathy. Int J Mol Sci. 2018;19(2) pii: E619.","DOI":"10.3390\/ijms19020619"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-019-1213-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13023-019-1213-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-019-1213-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,20]],"date-time":"2020-10-20T23:24:33Z","timestamp":1603236273000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-019-1213-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,22]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["1213"],"URL":"https:\/\/doi.org\/10.1186\/s13023-019-1213-3","relation":{},"ISSN":["1750-1172"],"issn-type":[{"type":"electronic","value":"1750-1172"}],"subject":[],"published":{"date-parts":[[2019,10,22]]},"assertion":[{"value":"3 July 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 September 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 October 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"As this was a single patient experimental treatment trial in a palliative setting no ethic approval was required. The patients\u2019 parents gave their informed written consent for the treatment trial.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The patients\u2019 parents gave their informed consent for the publication of this case report.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"231"}}